Related Experiment Videos
A specific defect in the retinoic acid response associated with human lung cancer cell lines
Abstract:
The effects of retinoic acid (RA) are mainly mediated by its nuclear receptors, the RA receptors (RARs) and retinoid X receptors (RXRs) that regulate target gene expression by binding to specific RA-response elements (RAREs). RAR beta is the best characterized RA-responsive gene. Due to the presence of a RARE (beta RARE) in its promoter, the expression of the RAR beta 2 is markedly increased in response to RA in most epithelial tissues, including lung. Recently, it was observed that the RAR beta gene is not expressed in a number of human lung cancer cell lines, suggesting a possible correlation between abnormal expression of the RAR beta gene and lung cancer development. In this study, we investigate the RA response in human lung cancer cell lines. Here we report that the expression of the RAR beta gene cannot be regulated by RA in the majority of human lung cancer cell lines examined, while the general response to RA is intact. The nonresponsiveness of the RAR beta gene results from different defects in the response mechanism. Interestingly, we find in some cell lines a differential responsiveness of the beta RARE such that the element is inactive in its natural promoter context but active when linked to the heterologous tk promoter. Importantly, we also observe that the presence of retinoid receptors is not sufficient for the induction of the RAR beta gene. This suggests that specific factors determine the RA responsiveness in the context of its natural promoter. Our observation that the RA nonresponsiveness of the RAR beta promoter is a common feature of human lung cancer cell lines suggests that balanced RAR beta expression is an essential feature for the maintenance of a normal state of lung tissue.
Insights
Retinoic acid (RA) normally regulates gene expression via nuclear receptors. However, lung cancer cell lines often fail to regulate the RAR beta gene in response to RA, indicating a potential link to cancer development.
Area of Science:
- Molecular biology
- Cancer research
- Gene regulation
Background:
- Retinoic acid (RA) signaling is crucial for cellular processes, mediated by retinoic acid receptors (RARs) and retinoid X receptors (RXRs).
- RAR beta is a well-characterized RA-responsive gene, with its expression typically induced by RA through a specific response element (beta RARE) in its promoter.
- Abnormal RAR beta gene expression has been observed in human lung cancer cell lines, suggesting a potential role in lung cancer development.
Purpose of the Study:
- To investigate the retinoic acid (RA) response in human lung cancer cell lines.
- To determine the mechanisms underlying the nonresponsiveness of the RAR beta gene to RA in these cell lines.
- To explore the implications of RAR beta dysregulation in lung cancer.
Main Methods:
- Analysis of RAR beta gene expression in response to RA in various human lung cancer cell lines.
- Investigation of the functionality of the beta RARE in its natural promoter context and when linked to a heterologous promoter.
- Assessment of the sufficiency of retinoid receptor presence for RAR beta gene induction.
Main Results:
- The majority of human lung cancer cell lines examined showed a lack of RA-mediated regulation of the RAR beta gene, despite an intact general RA response.
- Nonresponsiveness was attributed to defects in the RAR beta gene regulation mechanism.
- The beta RARE exhibited differential responsiveness, being inactive in the native promoter but active with a heterologous promoter, and retinoid receptor presence alone was insufficient for RAR beta induction.
Conclusions:
- Dysregulation of RAR beta gene expression is a common feature in human lung cancer cell lines.
- Specific factors, beyond receptor presence, are critical for RA responsiveness within the RAR beta gene's natural promoter.
- Balanced RAR beta expression appears essential for maintaining normal lung tissue homeostasis, and its disruption may contribute to lung cancer development.